PATEXUS detects single-nucleotide differences in DNA outside the laboratory — without amplification, without enzymatic reagents, without a cold chain. Results in 15 to 30 minutes.
Conventional rapid tests are chemistry — PCR, enzymes, reagents, DNA copying. PATEXUS is physics: spin-dependent plasmonic resonance on a carbon-nanotube sensor. No amplification, no enzymatic reactions, no thermocycling, no cold chain. The only consumable is a single-use sensor chip.
Plasmonically enhanced Raman scattering on the nanotube sensor reads the diagnostic 1462–1472 cm⁻¹ band — a molecular fingerprint, without thermal cycling.
The electrical signature of DNA binding is measured in real time on the nano-structured sensor surface.
An exact match (homoduplex) and a single-base mismatch (heteroduplex) quench the fluorescent label to different degrees — resolving the difference of one letter.
Rapid tumor-marker and SNP profiling at the point of care.
Genotype drug-metabolism variants before dosing.
Pathogen and resistance markers in low-resource settings.
Fast, decentralized detection of actionable variants.
Field identification of genetic threat signatures.
HLA and rejection-related genotyping near the patient.
Foundational data were generated for the KRAS (codon 12) mutation and on FFPE tissue. The application areas above are development directions and require clinical validation.
A PCT international patent application has been filed (PCT/IB2025/059881). The International Search Report and Written Opinion issued a positive opinion — affirming novelty, inventive step, and industrial applicability for all claims. The technology is at proof-of-concept stage; the next steps are clinical validation and national-phase patent filings, including the United States.
For scientific and partnership inquiries.
[email protected]